Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)
暂无分享,去创建一个
T. Murakami | M. Kudo | K. Ueshima | J. Furuse | K. Hasegawa | M. Sakamoto | M. Ikeda | S. Shiina | R. Tateishi | N. Kokudo | T. Yamashita | S. Miyayama
[1] K. Ikeda. Recent advances in medical management of hepatocellular carcinoma , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.
[2] Y. Imai,et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. , 2018, The lancet. Gastroenterology & hepatology.
[3] T. Meyer,et al. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[4] M. Kudo,et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. , 2017, Journal of hepatology.
[5] Y. Nakamoto. Promising new strategies for hepatocellular carcinoma , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[6] Tetsuya Ikemoto,et al. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[7] T. Murakami,et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.
[8] A. Russo,et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis , 2015, PloS one.
[9] Y. Imai,et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.
[10] M. Kudo,et al. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma , 2014, Journal of Gastroenterology.
[11] M. Makuuchi,et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version) , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[12] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[13] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[14] M. Yoshikawa,et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. , 2000, AJR. American journal of roentgenology.
[15] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[16] M. Palmer,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.